Dr. Dipti Doshi MD

GLG News by Dr. Dipti Doshi MD, Rheumatologist

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion.

May 1, 2008

Analysis of:Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis | www.pipelinereview.com

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab, Orencia, Rituximab . Biologics are typically reserved for patients with moderate to severe RA who require add-on therapy, estimated to be approximately 40 percent of the RA population. SBI-087 in phase-1 clinical trial to evaluate safety, tolerability , pharmacodynamics in RA with function class I, II or III diagnosed more than six month prior to surgery. Mechanisms Of Action: Therapeutic monoclonal antibodies (mAbs) typically act through three significant potential mechanisms of action: • Complement dependent cytotoxicity (CDC) • Antibody-dependent cellular cytotoxicity (ADCC) • Apoptosis (programmed cell death) All CD20-directed mAb therapies result in temporary B-cell depletion.

Phase 2 study showing that a 1mg treatment with Adlea(TM) effective for 12 week persistant pain in OA patients

July 4, 2007

Analysis of:Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee | www.pipelinereview.com

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is particularly important in this typically elderly and vulnerable patient population and may potentially offer a safer treatment option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect resulting from a single or stepped dose, localized administration of Adlea does not seem to be associated with the systemic side effects commonly associated with NSAIDs (gastrointestinal and renal toxicities, and impaired clotting), COX-2 inhibitors (cardiovascular risks and renal toxicity), or opioids (respiratory depression, nausea/vomiting, sedation, disorientation, physical dependence, and the risk of addiction).

Roche's market share will go up .

June 18, 2007

Analysis of:New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis | pharmalive.com

Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.

SRV in non responders

May 28, 2007

Analysis of:"Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" | www.natap.org

Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug

Page : 11 to 4 of 4